Vir Biotechnology, Inc. (VIR)

10.83 -4.24% (-0.48)

Over 3Y: -15.7%

2026-08-28
Style
Area Line Line with markersneeds a shorter window Steps Candlesneeds a shorter window Hollow candlesneeds a shorter window Barsneeds a shorter window

Candles need the day’s open, high and low. Those are being collected now — a company shows them once its history has been refreshed.

5 10
2023 2024 2025 2026

Financials Quarterly

Figures
Revenue Gross Profit Operating Income Cost of Revenue Operating Cash Flow Free Cash Flow Net Income

A share count and earnings a share are not here: neither is money, so neither can share this axis. Both have their own panel on All charts.

All charts ›
Q3 '25 — Revenue: 240K Q3 '25 — Operating Cash Flow: -167.6M Q3 '25 — Free Cash Flow: -167.9M Q3 '25 — Net Income: -163.1M Q4 '25 — Revenue: 64.1M Q4 '25 — Operating Cash Flow: -25.9M Q4 '25 — Free Cash Flow: -26.2M Q4 '25 — Net Income: -42.9M Q1 '26 — Revenue: -29K Q1 '26 — Operating Cash Flow: -132.4M Q1 '26 — Free Cash Flow: -132.8M Q1 '26 — Net Income: -125.7M Q2 '26 — Revenue: 238.9M Q2 '26 — Operating Cash Flow: 123.3M Q2 '26 — Free Cash Flow: 123.3M Q2 '26 — Net Income: 80.1M -90M 0 90M 180M 270M
Q3 '25 Q4 '25 Q1 '26 Q2 '26
Revenue Operating Cash Flow Free Cash Flow Net Income

Figures as at 2026-06-30, reported in USD. The newest fact in the filings is dated 2026-06-30, 61 days ago. Nothing on this page is advice.

How it scores

Five questions, each answered by the measures under it. Every figure is the company's own; the bar beside it is where that figure sits among the companies read here — the top fifth, the bottom fifth, or somewhere between. Not among all listed companies, and for a valuation multiple the low end is the good end.

Quality

How much of the revenue is really kept — and what did it take to earn it?

1.3
SBC / sales 15.5%
OE margin -82.7%
Oper. margin -92.4%
ROIC -48.8%
Accruals -4.0%
EBITDA margin -88.6%
FCF margin -67.1%
OCF margin -66.8%
Profit margin -83.0%
ROA -20.7%
ROCE -25.0%
ROE -25.6%
Gross margin —
OCF / EBIT —

5 of 17 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Valuation

What does the price ask for what the company earns, owns and pays out?

0.5
Div. yield —
EV/EBIT —
EV/GP —
EV/OE —
EV/Sales —
FCF yield —
Fwd P/E —
P/B —
P/C —
P/E —
PEG —

0 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Durability

How predictable is the revenue, and how much of it is already committed?

2.0
RPO / sales —
RPO growth —
Segment HHI —

3 of 7 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Resilience

Can the balance sheet absorb a bad year?

7.3
ND/EBITDA —
Cash runway 2.6 yr
Debt / Eq 0.0×
Debt payback 0.0 yr
Quick ratio 6.0×
F-score 3.4 pts
Cash / Debt —
Interest cover —
Payout —

3 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Growth

Is the business getting bigger, and is it getting more profitable?

5.2
Sales/sh Y/Y +1469.7%
Sales CAGR 4Y -50.0%
Sales Q/Q +19582.5%
Div. growth —
EBIT CAGR —
EBIT Y/Y —
EPS CAGR 4Y —
EPS Y/Y —
EPS next Y —

4 of 13 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

A measure absent from a block could not be computed from this company's filings. It is left out rather than scored as though it were bad, and the dimension is averaged over what remains. A score is measured against a fixed scale this model states; the bar is measured against the other companies, so the two can disagree — and where they do, that disagreement is the more interesting figure.